GenesisCare
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GenesisCare - overview
Established
2006
Location
Waterlooville, England, UK
Primary Industry
Healthcare
About
GenesisCare, based in the UK, is a leading provider of comprehensive cancer care, focusing on advanced radiation oncology services alongside personalized medicine and therapeutic innovations. Founded in 2006 in Waterlooville, UK, GenesisCare specializes in cancer care, particularly radiation oncology. The company has made strategic acquisitions, including the acquisition of Cancer Partners UK Limited in July 2015. GenesisCare operates multiple treatment centers, enhancing its service delivery across international markets.
GenesisCare specializes in comprehensive cancer care, focusing on radiation oncology and expanding into medical oncology, theranostics, and personalized medicine. The company operates over 40 treatment centers across Australia, offering advanced therapeutic options such as brachytherapy and external beam radiation therapy. Their services cater to various cancer types, including breast, lung, prostate, and skin cancers, serving around 30,000 patients annually, with a growing presence in select international markets through clinical partnerships. In the most recent year, GenesisCare reported a revenue of USD 200.
51 mn and an EBITDA of USD 24. 83 mn. The company's revenue structure relies on direct transactions with patients and healthcare partners for cancer treatment services, emphasizing both B2B and direct-to-consumer models. GenesisCare's growth strategy includes expanding its presence in new geographic regions, aiming to enhance its market footprint internationally by targeting partnerships in Europe and North America.
The company plans to utilize its recent acquisition to bolster its service offerings and patient accessibility. The acquisition of Cancer Partners UK Limited in July 2015 is an integral part of this strategy, enabling the company to provide a broader range of cancer treatments.
Current Investors
KKR, Genesis Care Pty Limited
Primary Industry
Healthcare
Sub Industries
Hospitals, Clinics/Outpatient Services, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment
Website
www.genesiscare.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
GenesisCare - timeline of key events
GenesisCare - financials
| Fiscal Year Ended | Jun 30, 2011 | Jun 30, 2012 | Jun 30, 2013 | Jun 30, 2014 | Jun 30, 2015 | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2020 | Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 8,935,280 | 12,535,811 | 17,038,615 | 19,703,305 | 23,811,797 | 29,211,624 | 34,074,451 | 40,415,877 | 56,668,292 | 76,524,000 | 85,114,000 | 100,351,000 | - | - | - |
| % Revenue Growth (YoY) | - | 40.3% | 35.9% | 15.6% | 20.9% | 22.7% | 16.6% | 18.6% | 40.2% | 35.0% | 11.2% | 17.9% | - | - | - |
| EBITDA (USD) | 3,497,616 | 5,674,150 | 7,949,580 | 6,825,566 | 7,606,294 | 9,329,780 | 10,564,304 | 8,915,545 | 9,717,225 | 16,272,000 | 6,950,000 | 15,139,000 | - | - | - |
| Operating Income (USD) | 2,527,179 | 4,455,478 | 6,362,629 | 4,448,688 | 4,535,297 | 6,231,004 | 6,600,222 | 4,002,282 | 2,570,120 | 5,711,000 | (5,482,000) | 1,699,000 | - | - | - |
| Operating Margin | 28.3% | 35.5% | 37.3% | 22.6% | 19.0% | 21.3% | 19.4% | 9.9% | 4.5% | 7.5% | (6.4%) | 1.7% | - | - | - |
| % EBITDA Margin | 39.1% | 45.3% | 46.7% | 34.6% | 31.9% | 31.9% | 31.0% | 22.1% | 17.1% | 21.3% | 8.2% | 15.1% | - | - | - |
| NET Income (USD) | 1,374,563 | 1,375,407 | 2,798,333 | 1,737,178 | 672,331 | 5,882,732 | 6,540,617 | 3,265,026 | 1,791,443 | 1,858,000 | (9,196,000) | (1,233,000) | - | - | - |
| % Net Margin | 15.4% | 11.0% | 16.4% | 8.8% | 2.8% | 20.1% | 19.2% | 8.1% | 3.2% | 2.4% | (10.8%) | (1.2%) | - | - | - |
GenesisCare - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | GenesisCare | - | ||||||||
| Company Formation | Completed | GenesisCare | - |
Displaying 1 - 2 of 2
GenesisCare - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.